Alejandro González Veliz: Most Reported Aspirin Allergies Are Not True Hypersensitivity
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn about recent article by Silvia Grimaldi et al., published in European Heart Journal, adding:
“Aspirin remains one of the most important drugs in cardiovascular medicine.
Yet many patients arrive with a history of ‘aspirin allergy,’ often leading clinicians to avoid a therapy that may be crucial after PCI, ACS, or valve interventions.
The reality?
Most reported reactions are not true hypersensitivity.
A careful history can distinguish intolerance from genuine allergy, and for selected patients, aspirin desensitization can safely restore access to guideline-directed therapy.
Understanding this distinction may prevent treatment delays, suboptimal antiplatelet strategies, and potentially avoidable cardiovascular events.”
Title: Aspirin hypersensitivity: a practical guide for cardiologists
Authors: Silvia Grimaldi, Paola Migliorini, Ilaria Puxeddu, Roberta Rossini, Raffaele De Caterina
Other posts featuring Alejandro González Veliz on Hemostasis Today.
-
Jul 17, 2026, 20:19Thomas Muenzel: Proud to Deliver the Sylviane Lévy-Toledano Memorial Plenary Keynote Lecture at ISTH 2026
-
Jul 17, 2026, 20:16Karin Leiderman: Proud of Jamie Madrigal for Receiving the JTH Editors’ Award
-
Jul 17, 2026, 20:14Lily Bull: Presenting New Research and Building Connections at ISTH 2026
-
Jul 17, 2026, 20:12Modern Concepts in Traumatic Disseminated Intravascular Coagulation – JTH
-
Jul 17, 2026, 20:10Nahid A. Qushmaq: Science, Collaboration, and Inspiration at ISTH 2026
-
Jul 17, 2026, 18:20Sarah Jones: Bringing Vessel-on-a-Chip Research to ISTH 2026
-
Jul 17, 2026, 18:06Virginia Barras Sánchez: United by a Commitment to Hemophilia at ISTH 2026
-
Jul 17, 2026, 17:53Micah Grey: Shaping the Future of Hematology at ISTH 2026
-
Jul 17, 2026, 17:32Vasiliki Danilatou: Advancing β-Thalassemia Research at ISTH 2026